a A Proud to be a Banner Health Center of Excellence

Studies Currently Enrolling

Studies for participants without memory loss

API Generation Study: A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease 

CAPI015A2201J: A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease.

Sponsors:
Novartis Pharmaceuticals
Banner Alzheimer’s Institute
National Institute on Aging (NIA)
Alzheimer’s Association
Amgen

Condition: Individuals at increased risk

ClinicalTrials.gov identifier: NCT02565511 

Drug: CAD106 and CNP520

 

Ages Eligible for Study:

60-75 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The purpose of this study is to assess the effects of two investigational drugs, CAD106 and CNP520, when administered separately. This study is evaluating whether these drugs can slow down the onset and progression of clinical symptoms associated with Alzheimer’s disease in participants who are at an increased risk to develop symptoms based on their age and genetic status.

Learn more: Generation Study  

 

An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY) 

Sponsor: Janssen Research & Development

 

Condition: Cognitively normal individuals at increased risk for developing Alzheimer’s dementia 

ClinicalTrials.gov identifier: NCT02569398  

Drug: JNJ-54861911

 

Ages Eligible for Study:

60*-85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The primary objective of this study is to determine whether treatment with JNJ- 54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive subjects who are asymptomatic at risk for developing Alzheimer’s dementia.

*Participants age 60-64 must meet one of the following criteria: 1) Family history of dementia, 2) Known APOE e4 status, OR 3) Known amyloid status (positive for elevated amyloid). 

 

GeneMatch

The GeneMatch program is part of the Alzheimer’s Prevention Registry that aims to identify a large group of people who are interested in participating in Alzheimer’s research studies or clinical trials based in part on genetic information.

Sponsor: Banner Alzheimer’s Institute

Condition

Individuals with normal memory and thinking who may be at increased risk for Alzheimer’s disease

ClinicalTrials.gov identifier: NCT02564692

 

 

Ages Eligible for Study:

55-75 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The primary purpose of GeneMatch is to advance Alzheimer’s research by helping scientists find enough qualified participants to launch new studies based in part on their genetic information. GeneMatch will provide interested individuals with a cheek swab kit in order to collect information on which copies of a gene (known as the APOE type allele) they have. Individuals who participate will not be told their genetic results, but they may be contacted about study opportunities in their area.

Learn more: GeneMatch 

 

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

H8A-MC-LZAZ/ADC-040-A4: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

Sponsor: Eli Lilly and Company

Condition: Cognition Disorders

ClinicalTrials.gov identifier: NCT02008357    

Drug: Solanezumab

 

Ages Eligible for Study:

65-85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The A4 Study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains and may be at risk for memory loss and cognitive decline due to Alzheimer’s disease. The A4 Study will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer’s disease, cognitive impairment or dementia. The intent is to slow memory and cognitive decline. The A4 Study will also test whether anti-amyloid treatment can delay the progression of AD related brain injury on imaging and other biomarkers.

Learn more: The A4 Study

 

Brain Imaging, APOE & the Preclinical Course of Alzheimer’s Disease Study

ClinicalTrials.gov identifier: n/a

Ages Eligible for Study:

47-68 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

This study is sponsored by the National Institutes of Health (NIH) and is a long-term study that seeks to better understand the course of Alzheimer’s disease before clinical symptoms emerge. This brain imaging study, a collaboration with Mayo Clinic, will follow individuals indefinitely. The purpose is to observe the course of aging in participants with different genetic risk levels of developing different memory problems. The study includes visits every two years. Imaging visits include MRIs and PET scans. The study also includes optional lumbar punctures. Participants do not require a study partner.

 

Studies for participants with and without memory loss

Alzheimer’s Disease Core Center (ADCC)

Sponsor: University of Arizona
Collaborators: Banner Alzheimer’s Institute
Banner Sun Health Research Institute
Barrow Neurological Foundation
Mayo Clinic
National Institute on Aging (NIA)
National Institutes of Health (NIH)

Conditions:

Alzheimer’s Disease

Mild Cognitive Impairment

Age-Related Memory Disorders

ClinicalTrials.gov identifier: NCT01421420

 

 

Ages Eligible for Study:

40 years & older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched normal controls. The study will also attempt to identify cognitively normal individuals at genetically defined risk for Alzheimer’s disease through genetic screening.

All participants are seen annually. Autopsies to establish diagnoses in patients with dementia, patients with mild MCI, and cognitively normal elderly control subjects will also be conducted

 

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Sponsor: University of Southern California
Collaborators:
Northern California Institute of Research and Education
National Institute of Aging (NIA)
Alzheimer’s Therapeutic Research Institute (ATRI)

Conditions:

Individuals with Normal Thinking and Memory

Mild Cognitive Impairment

Alzheimer’s Disease

ClinicalTrials.gov identifier: NCT02854033 

 

 

Ages Eligible for Study:

55-90 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

Yes

 

ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of Alzheimer’s disease (AD). This is a natural history, non-treatment study. Clinical/cognitive measures, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: Cognitively Normal, Mild Cognitive Impairment (MCI), and mild AD dementia. If you are eligible and agree to participate, your participation in this study will last between 3 and 5 years, depending on which study group you fit in.

Learn more: ADNI 3

 

Studies for participants with memory loss

221AD302: A Clinical Trial to Evaluate the Efficacy and Safety of the Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease

Sponsor: Biogen MA, Inc.

Condition: Mild Cognitive Impairment

ClinicalTrials.gov identifier: NCT02484547 

Drug: Aducanumab (BIIB037)

 

Ages Eligible for Study:

50-85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

The primary objective of this study is to evaluate the effectiveness of monthly doses of aducanumab in slowing both functional and cognitive impairments in adults with Mild Cognitive Impairment. Changes in impairment will be measured using the scores of cognitive tests as compared with placebo. Additional objectives are to evaluate the long-term safety and tolerability profile and evaluate long-term effectiveness of aducanumab measured by numerous clinical assessments.

 

D5010C00009:  An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease (AMARANTH)

Sponsor: Eli Lilly and Company

Condition: Alzheimer’s disease or Mild Cognitive Impairment 

ClinicalTrials.gov identifier: NCT02245737   

Drug: AZD3293

 

Ages Eligible for Study:

55-85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

The purpose of this study is to assess the efficacy and safety of AZD3293 compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that AZD3293 is a disease-modifying treatment for patients with early Alzheimer´s disease, defined as the continuum of patients with Moderate Cognitive Impairment (MCI) due to Alzheimer’s disease and patients diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline in the Clinical dementia Rating-Sum of Boxes score at week 104 in each of the two AZD3293 treatment groups compared with placebo.

 

Aware – A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease

Sponsor: AbbVie

 

Condition: Mild Cognitive Impairment or early Alzheimer’s disease

ClinicalTrials.gov identifier: NCT02880956

Drug: AbbVie M15-566

 

Ages Eligible for Study:

55-85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:   

No

 

The purpose of the Aware Study (AbbVie M15-566) is to slow the progression of symptoms associated with Alzheimer’s (cognitive and functional decline), at the early stages of the disease. Participation in the Aware study will last approximately two years, which includes a screening period, a study-treatment period and then a follow up after treatment. The screening period can last up to eight weeks, during that time participants will be asked to take part in a number of procedures such as: ECG, imaging procedures (MRI, PET), a lumbar puncture, and provide blood and urine samples. Participants will also provide their medical and medication history. During the treatment period of the study, participants will be asked to return every four weeks for IV infusion. Participants must have a study partner to take part in the Aware study.

 

CREAD -  A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD)

Sponsor: Hoffmann-LaRoche

 

Condition: Alzheimer’s Disease

ClinicalTrials.gov identifier: NCT02670083  

Drug: Crenezumab

 

Ages Eligible for Study:

55-85 years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

Half of the participants enrolled in the study will receive the investigational study medication. The other half will receive a placebo, which looks just like the investigational study medication, but contains no active ingredient. Both the investigational study medication and the placebo will be given as an intravenous infusion (which you may hear referred to as an ‘IV’ or ‘drip’).

The CREAD clinical research study is designed to see how an investigational study medication can affect the progression of prodromal (early) to mild Alzheimer’s disease. The study will last for approximately three years, including a screening period lasting up to 8 weeks to assess suitability, two years of study medication and one year of follow-up. During the two-year dosing period, participants will receive the investigational study medication or a placebo every four weeks. At these visits, there will be some study-related assessments to monitor your health and condition. After this time, there may be an open-label extension study that you may be able to enter, where all participants receive the investigational study medication and no one receives a placebo.

 

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer’s Disease – Phase 2a Study 

Sponsor: Suven Life Sciences Limited

Condition: Moderate Alzheimer’s 

 

ClinicalTrials.gov identifier: NCT02580305    

Drug: SUVN-502

 

Ages Eligible for Study:

50-85 years 

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:    

No

 

The purpose of the SUVN-502 Study is to see whether SUVN-502 – has an effect on the symptoms of Alzheimer’s disease when given along with the standard treatments, donepezil and memantine. The SUVN-502 Study will involve approximately 530 people with Alzheimer’s disease across 90 study centers in the USA. Not everyone will be able to join the study as several joining criteria must be met. It is voluntary to join the study. You can leave at any time for any reason without having to explain why. Participants and their study partners will attend five clinic visits over the 26-week treatment phase. During these visits, the study team will check on the participant’s symptoms and overall health using standard medical tests, questionnaires, and interviews. All study medication will be one tablet, to be taken once every day for the 26-week treatment period. All participants will also continue to take their existing Alzheimer’s treatment throughout the entire 30 weeks, which will be: Donepezil 10 mg once daily, plus Memantine 10 mg twice daily / Namenda XR® 28 mg once daily / or as part of combination therapy Namzaric™ (28 mg memantine HCI/10 mg donepezil HCI qd).